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Abstract
Eps8 is involved in both cell signalling and receptor trafficking. It is a known phosphorylation substrate for two proteins
involved in the fibroblast growth factor receptor (FGFR) signalling pathway: the receptor itself and Src. Here we report
a differential proteomic analysis of Eps8 aimed to identify specific FGFR and Src family kinase dependent phosphosites and
co-associated phosphodependent binding partners. This study reveals a total of 22 Eps8 pTyr and pSer/Thr phosphorylation
sites, including those that are dependent on Src family and FGFR kinase activity. Peptide affinity purification of proteins that
bind to a selection of the pTyr phosphosites has identified a range of novel Eps8 binding partners including members of the
intracellular vesicle trafficking machinery (clathrin and AP-2), proteins which have been shown to regulate activated
receptor trafficking (NBR1 and Vav2), and proteins involved in receptor signalling (IRS4 and Shp2). Collectively this study
significantly extends the understanding of Eps8 post-translational modification by regulated phosphorylation, identifies
novel Eps8 binding partners implicated in receptor trafficking and signalling, and confirms the functions of Eps8 at the
nexus of receptor signalling and vesicular trafficking.
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Introduction
Eps8 is involved in modulating cell signalling and receptor
trafficking, via its range of protein interactions. When bound in
a complex with Abi1and Sos1, Eps8 participates in signal
transduction from Ras to Rac, leading to actin remodelling [1].
The SH3 domain of Eps8 binds Abi1 [1,2] and, essential to its role
in Rac activation, Sos1 binds the C-terminal effector region [3].
Coexpression of this Eps8-Abi1-Sos1 tri-complex has been
correlated with advanced stage ovarian cancer, shown to be
attributed to increased Rac-induced cell migration [4]. Interaction
with the RabGAP, RN-Tre, via its SH3 domain, disrupts this tri-
complex enabling Eps8 to participate in receptor trafficking via de-
activation of Rab5 [5]. In addition, Eps8 is involved in actin
capping and bundling via its interactions with IRSp53 and
monomeric actin [6,7].
Eps8 was originally identified as a novel phosphorylation
substrate for the epidermal growth factor receptor (EGFR) and
is also phosphorylated upon activation of other tyrosine kinases
including fibroblast growth factor receptor (FGFR), platelet-
derived growth factor (PDGF) and erbB-2 [8]. It has since been
identified as a phosphorylation substrate for Src [9] and elevated
expression of Eps8 has been observed in v-Src transformed cells
[9,10] and a variety of human cancers [11,12,13]. Phosphorylation
is an important post-translational modification in the regulation of
protein-protein interactions constituting cellular signal transduc-
tion, and aberrant regulation of phosphorylation can lead to
malignancy. Indeed, constitutive phosphorylation of Eps8 has
been found in a range of tumour cell lines [14].
Previously, we used quantitative proteomics to identify candi-
date mediators of FGFR signalling which are targets for Src family
kinase (SFK)–mediated phosphorylation and functionally impli-
cated in trafficking of activated FGFRs [15]. Eps8 was one such
protein identified in this survey.
Collectively these features identify Eps8 as a potential target for
transmitting FGFR and Src mediated signalling events to
downstream effectors which warranted a detailed investigation of
both FGFR and SFK mediated phosphorylation of Eps8 and
analysis of phospho-dependent Eps8 binding partners to identify
further candidate effectors and provide some insight into the
possible pathways that these phosphorylation events influence.
Using quantitative mass spectrometry techniques [16,17,18]
coupled with chemical inhibition of FGFR and SFK kinase
activity we have carried out phosphopeptide mapping of Eps8 in
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order to identify FGFR and SFK-regulated phosphorylation sites.
In addition, differentially recruited phosphodependent protein
partners have been identified using quantitative peptide pull down
(PPD) assays. This technique has revealed many novel Eps8
binding partners including insulin-receptor substrate 4 (IRS4).
Previous proteomic studies have implicated IRS4 in FGFR
signalling [19,20]. Here we have identified IRS4 as a novel
binding partner for an Eps8 peptide containing phosphorylated
Tyr252. Furthermore, we show that the interaction between Eps8
and IRS4 and their colocalisation within cells is increased
following FGFR activation which coincides with tyrosine phos-
phorylation of both Eps8 and IRS4.
These results significantly expand the range of proteins
implicated to interact with Eps8, illustrating further its role as
a multi-functional adaptor molecule mediating FGFR and Src
kinase signalling.
Materials and Methods
Cell Culture
Human embryonic kidney epithelial 293T cells and mouse NIH
3T3s were cultured at 37uC, 5% CO2 in DMEM containing
2 mM L-Glutamine (Lonza), supplemented with 0.1 mg/ml
streptomycin, 0.2 U/ml penicillin (Sigma), and 10% v/v fetal calf
serum (Labtech International). For SILAC labelling, 293T cells
were cultured in SILAC DMEM (Thermo Fisher Scientific)
supplemented with either 0.1 mg/ml ‘‘light’’ isotopically normal
L-Lysine and L-Arginine (R0K0) (Sigma), ‘‘medium’’ 13C6 L-
Lysine and 4,4,5,5-D4 L-Lysine (R6K4), or ‘‘heavy’’ 13C6
15N4 L-
Arginine and 13C6
15N2 L-Lysine (R10K8) (Goss Scientific),
0.5 mg/ml proline (Sigma), 0.1 mg/ml streptomycin, 0.2 U/ml
penicillin, and 10% v/v dialysed fetal bovine serum (Labtech
International).
Cloning and Transfection
The human open reading frames for Eps8 and IRS4 were
supplied in Gateway (InvitrogenTM) pDONR vectors from Open
Biosystems. The insert encoding Eps8 was cloned into the
Gateway compatible mammalian expression vector, Myc-PRK5
(gift from Laura Machesky) using Gateway cloning. The insert
encoding IRS4 was cloned into the Gateway mammalian
expression vector, pDEST53 (GFP-tag) using Gateway cloning.
Eps8-mCherry was a gift from Giorgio Scita (IFOM University of
Milan, Milan, Italy). HEK 293T cells were transfected using
Genejuice (Novagen) and NIH 3T3 cells were transfected using
Lipofectamine2000 (Invitrogen) according to manufacturer’s
instructions. Cells were allowed to overexpress transfected protein
for 48 h.
Cell Treatment and Cell Lysis
Following overnight serum starvation in media containing 0.1%
serum, cells were either pre-treated with SU6656, dasatinib or
SU5402 for 30 min, followed by addition of 20 ng/ml FGF2, or
treated as above in the absence of chemical inhibitor. For
experiments where cells were treated with sodium pervanadate,
2 mM sodiumpervanadate was added to themedia for 20 min prior
Figure 1. Chemical inhibition of Src kinase and FGFR kinase activity. A) HEK 293T cells were treated with SU5402, SU6656, or dasatinib
30 min prior to addition of FGF2 for 15 min. Cells were lysed and analysed by western blotting. B) HEK 293T cells were treated with increasing
concentrations of dasatinib for 30 min prior to addition of FGF2 for 15 min. Cells were lysed and analysed by western blotting.
doi:10.1371/journal.pone.0061513.g001
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to FGF2 stimulation. Cell lysis and measurement of total protein
concentrations were performed as described previously [15].
Immunoprecipitation and Western Blotting
Antibodies were purchased from Roche (Myc 9E10), Santa Cruz
(Eps8 sc-1841; Clathrin HC sc-12734; Vav2 sc-20803; Shp2 sc-424;
IRS4 sc-100854; AP-2 sc-10761; PHB sc-28259; PHB2 sc-133094;
ERK sc-94; p-ERK sc-7383), NEB (Src 2110, p-Src 2101, STAT3
9139), and Abcam (NBR1 ab55474). For IPs, antibodies were
conjugated to Protein G Dynabeads (Invitrogen), as per manufac-
turer’s instructions. For SILAC anti-Myc IPs, anti-Myc antibody
was further cross-linked to the beads: the conjugated Dynabeads
were washed twice in a 10-fold excess of 0.2 M triethanolamine
pH8.2. Beads were then resuspended in a 10-fold excess of freshly
prepared 20 mM dimethyl pimelidate dihydrochloride (DMP)
(Sigma) and mixed for 30 mins at room temperature followed by
washing in a ten-fold excess of 50 mM Tris/HCl for 15 mins at
room temperature and further washes (x3) in a 10-fold excess of
PBS/0.1% Tween 20 (PBS-T). Cross-linked beads were resus-
pended in PBS, prior to addition of whole cell lysate (WCL). WCLs
were mixed at 4uC with anti-Myc beads for 30 min, prior to
washing. For SILAC experiments, WCLs from the heavy, medium,
and light cell populations were immunoprecipitated separately
(10 mg WCL) and beads were mixed following five washes in a 20-
fold excess of lysis buffer. Following addition of reduced sample
buffer, samples were boiled for 5 min, run on 4–12% Bis-Tris gels
(Invitrogen) and Coomassie stained. Western blotting was per-
formed as previously described [15].
Peptide Pull Downs
Phosphorylated and non-phosphorylated peptide pairs were
synthesised by Alta Bioscience, Birmingham, UK. Each peptide
was synthesised with an N-terminal desthiobiotin. Peptides were
bound to MyOne Streptavidin Dynabeads (Invitrogen) (2.5 mg/
50 ml beads) by incubating at room temperature for 1 hour.
Peptide-bound beads were washed for 15 min65 in a 20-fold
excess of PBS-T. Heavy SILAC labelled (R10K8) WCL (10 mg)
was incubated with 50 ml beads bound to the phosphorylated
peptide, medium SILAC labelled (R6K4) WCL (10 mg) was
incubated with 50 ml beads bound to the non-phosphorylated
peptide, and light SILAC labelled (R0K0) WCL (10 mg) was
incubated with 50 ml beads without peptide, overnight at 4uC.
PPDs were washed at least 5 times in a 20-fold excess of PBS-T.
Beads from each peptide pair and a non-peptide control were
combined. Following addition of reduced sample buffer, protein
samples were run on 4–12% Bis-Tris gels (Invitrogen) and
Coomassie stained.
Trypsin Digestion and Phosphopeptide Enrichment of
Samples
Trypsin digestion was carried out as previously described
[15,21]. From the excised band corresponding to Eps8, phospho-
peptides were enriched using TiO2 tips (GLSciences), according to
the manufacturer’s instructions. All resulting peptide mixtures
were analysed by liquid chromatography tandem mass spectrom-
etry (LC-MS/MS).
Figure 2. Representative mass spectra for identification and site localisation of tyrosine phosphorylation on Eps8. A) Eps8 is
phosphorylated on residue 525. B) Eps8 is phosphorylated on residue 540. pY indicates phosphotyrosine.
doi:10.1371/journal.pone.0061513.g002
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Figure 3. Differential regulation of tyrosine phosphorylation on Eps8. Heavy, medium and light SILAC labelled HEK 293T cells were treated
with either 25 nM dasatinib, 20 mM SU5402, or no inhibitor, prior to FGF2 stimulation (20 ng/ml; 15 min). Myc-Eps8 was immunoprecipitated and the
resulting sample was run on an SDS-PAGE gel and, following in-gel trypsin digestion and phophopeptide enrichment, analysed by mass
spectrometry. Each graph represents specific residues on Eps8 as indicated. Each data point represents a single peptide identification. P values were
calculated by an unpaired t-test (0.01–0.05 = *; 0.001–0.01= **; ,0.001 = ***). +, the median of the ratios is,the cut-off value of 0.57 and is deemed
significantly changed (see Method S1). A) Experiment was carried out in the absence of sodium pervanadate. B) Experiment was carried out in the
presence of 2 mM sodium pervanvadate.
doi:10.1371/journal.pone.0061513.g003
Phosphoproteomics of Eps8
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Mass Spectrometry
On-line liquid chromatography was performed by use of an
Dionex Ultimate 3000 LC system (Thermo Fisher Scientific).
Peptides were loaded onto an Acclaim PepMap 100 C18 resolving
column (15 cm length;75 mm internal diameter; LC Packings,
USA) and separated over a 40 minute gradient from 3.2% to 44%
Figure 4. Protein-peptide interaction network for proteins binding specifically to phosphotyrosine-containing Eps8 peptides. A)
Schematic diagram showing locations of the pY residues within the domain structure of Eps8. B) Using SILAC we carried out quantitative peptide
pull-down assays from FGF2 stimulated (20 ng/ml; 15 min) HEK 293T cells to compare protein-peptide interactions for phosphotyrosine versus non-
phosphotyrosine containing Eps8 peptides. Proteins interacting preferentially to phosphotyrosine peptides have been plotted in an interaction
network.
doi:10.1371/journal.pone.0061513.g004
Phosphoproteomics of Eps8
PLOS ONE | www.plosone.org 5 April 2013 | Volume 8 | Issue 4 | e61513
acetonitrile (Baker, Holland). Peptides eluted directly (350 nL/
min) via a Triversa nanospray source (Advion Biosciences, NY,
USA) into a LTQ Orbitrap Velos mass spectrometer (Thermo
Fisher Scientific). The mass spectrometer alternated between a full
FT-MS scan (m/z 380-1600) and subsequent CID MS/MS scans
of the twenty most abundant ions. Survey scans were acquired in
the Orbitrap cell with a resolution of 60,000 at m/z 400. Precursor
ions were isolated and subjected to CID in the linear ion trap.
Isolation width was 2 Th. Only multiply-charged precursor ions
were selected for MS/MS. CID was performed with helium gas at
a normalized collision energy of 35%. Precursor ions were
activated for 10 ms. Data acquisition was controlled by Xcalibur
2.1 software.
Identification and Quantification of Peptide and Proteins
Mass spectra were processed using the MaxQuant software
(version 1.0.13.13) [22,23]. Data were searched, using MASCOT
version 2.2 (Matrix Science), against a concatenated database
consisting of the human IPI database (version 3.72) supplemented
with common contaminants (including keratins, trypsin, BSA) and
the reversed-sequence version of the same database. The human
database contained 173,046 protein entries (86,523 of which were
reversed-sequence versions). The search parameters were: mini-
mum peptide length 6, peptide tolerance 7 ppm, mass tolerance
0.5 Da, cleavage enzyme trypsin/P, and a total of 2 missed
cleavages were allowed. Carbamidomethyl (C) was set as a fixed
modification and oxidation (M), acetylation (Protein N-term),
Figure 5. Full-length Eps8 interacts with a range of proteins
identified in the peptide pull down assays. HEK 293T cells were
either transfected with Myc-Eps8 or left untransfected. Cells were
stimulated with 20 ng/ml FGF2 for 15 min and immunoprecipitated
using an anti-Myc antibody. Western blot analysis was carried out on
whole cell lysate and immunoprecipitation samples using antibodies
against the indicated proteins.
doi:10.1371/journal.pone.0061513.g005
Figure 6. Eps8 and IRS4 interact in an FGF2 dependent manner that correlates with an increase in their tyrosine phosphorylation. A)
HEK293T cells transfected with Myc-Eps8 were stimulated with 20 ng/ml FGF2 for 15 min either following 30 min pretreatment with SU5402 or
dasatinib or in the absence of inhibitors. Anti-Myc immunoprecipitation and whole cell lysate samples were analysed by western blotting. B) HEK293T
cells were stimulated with 20 ng/ml FGF2 for different lengths of time and tyrosine phosphorylated proteins were immunoprecipitated. Anti-pY
immunoprecipitation and whole cell lysate samples were analysed by western blotting. C) HEK 293T cells were stimulated with 20 ng/ml FGF2 for
15 min and immnoprecipitations carried out using antibodies to either Eps8 or rabbit IgG. Resulting IP samples were analysed by western blotting. d)
Following 30 min treatment with SU5402 or dasatinib and stimulation with 20 ng/ml FGF2 for a further 15 min, endogenous IRS4 was
immunoprecipitated from HEK293T cells. Resulting IP samples were analysed by western blotting.
doi:10.1371/journal.pone.0061513.g006
Phosphoproteomics of Eps8
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Phospho (ST), and Phospho (Y) were set as variable modifications.
The appropriate SILAC labels were selected and the maximum
labelled amino acids was set to 3.
All experiments were filtered to have a peptide and protein
false-discovery rate (FDR) below 1%. Within the MaxQuant
output, phosphorylation sites were considered to be localised
correctly if the localisation score (PTM score) was at least 0.85
(85%). Additional information is listed in Method S1.
Confocal Microscopy and Quantification Analysis
Cells were fixed in 4% paraformaldehyde (PFA; Electron
Microscopy Sciences) in PBS for 10 min prior to analysis.
Confocal laser microscopy was performed with an inverted
microscope (Zeiss LSM 710) using a 4061.3NA oil-immersion
objective and a Transmission-Photomultiplier LSM T-PMT. Data
analysis was performed using NIS-Elements Imaging Software
version 3.2 (Nikon). The experiment was repeated 3 times and an
image that represented the phenotype of most of the cells was
selected.
Results and Discussion
Effects of SU5402 and Dasatinib on Eps8 Phosphorylation
Eps8 is a phosphorylation substrate for FGFR [8] and Src [9].
To identify the residues upon which these phosphorylation events
take place we have used a targeted mass spectrometric approach.
A quantitative SILAC technique coupled with chemical inhibition
of FGFR or SFK activity has been used to examine any differential
regulation in the phosphorylation of Eps8. Dasatinib is an SFK/
ABL kinase inhibitor approved for use in patients with chronic
myelogenous leukemia [24]. Here, dasatinib has been used to
inhibit SFK activity in preference to SU6656 [25], which was our
previous inhibitor of choice prior to dasatinib becoming commer-
cially available [15]. At concentrations needed to inhibit Src kinase
activity in HEK 293T cells, SU6656 also shows some inhibition of
FGFR activation, as measured by levels of phosphorylated ERK
(Figure 1A). Dasatinib does not show inhibition of FGFR induced
ERK activity, even at high concentrations (Figure 1B). SU5402,
has been used to inhibit the tyrosine kinase activity of FGFR1 [26]
and does not have any effect on phospho-Src levels (Figure 1A).
Using these compounds has allowed us to differentiate between
SFK-mediated and FGFR-mediated phosphorylation events on
Eps8 by comparing levels of phosphorylation in the presence of
dasatinib and SU5402.
We transfected three populations of HEK 293T cells, grown in
either ‘Light’ R0K0, ‘Medium’ R6K4, or ‘Heavy’ R10K8 SILAC
media, with Myc-Eps8. Cells were either left untreated (R0K0) or
pre-treated with SU5402 (R6K4) or dasatinib (R10K8) for 30 min
before stimulation with FGF2 for a further 15 min. Prior to mass
spectrometric analysis, phosphopeptide enrichment was carried
out on immunoprecipitated Myc-Eps8.
Figure 7. Eps8 and IRS4 colocalise within cells in an FGF2 dependent manner. NIH 3T3 cells were co-transfected with IRS4-GFP and Eps8-
mCherry. Cells stimulated with FGF2 (20 ng/ml) in the presence and absence of SU5402 (25 mM) were compared to unstimulated cells (control). A)
Confocal microscopy was used to visualise the localisation of IRS4 and Eps8. B) The colocalisation (Pearson’s coefficient) between IRS4 and Eps8 is
significantly increased in the presence of FGF2 and absence of SU5402 (Pearson’s coefficient, mean6SEM, n= 42 cells. Scale bars = 5 mm. ***,
P,0.001).
doi:10.1371/journal.pone.0061513.g007
Phosphoproteomics of Eps8
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A total of 22 distinct sites of phosphorylation (18 serines and 4
tyrosines) on Eps8 were identified (Table S1). Representative mass
spectra for two of the identified phosphopeptides are shown in
Figure 2 (see Figure S3 for additional spectra). The log-ratios for
each identification of phosphorylated peptide and non-phosphor-
ylated counterpart peptide are plotted in Figure 3 (tyrosine
residues) and Figure S1 (serine residues) and provide a visual
comparison of the relative ratios and number of peptide
identifications between non-treated and inhibitor treated samples.
Statistical methods for determining differential phosphorylation
are discussed by de la Fuente van Bentem et al. [27]. Our preferred
statistical method for deciding differential phosphorylation be-
tween samples is to use a t-test to directly compare non-
phosphorylated and phosphorylated counterpart peptides. How-
ever, the t-test has only been applied when there are three or more
replicates for each peptide. Another method to determine
differential phosphorylation is to select a cut-off for significant
statistics which is based on p-values determined from a test sample
(Method S1). This has been applied when only two identifications
have been made. Of the 4 tyrosine residues identified, 3
phosphotyrosine containing peptides (pY525, pY602, pY774)
had reduced SILAC ratios compared to their unphosphorylated
counterpart in the presence of both SU5402 and dasatinib,
indicating that the tyrosine phosphorylation on these particular
sites within Eps8 are sensitive to both FGFR and SFK activity
(Figure 3A).
Eps8 contains 20 tyrosine residues, and according to the
PhosphositePlus database [28], 9 of them have been found in their
phosphorylated form in the human protein. It may be that under
our experimental conditions in which the cells were stimulated
with FGF2, only the 4 tyrosines that we have identified are
phosphorylated. However, it is also possible that the levels of some
phosphopeptides remain too low for mass spectrometric detection.
Thus, in an attempt to increase the number of phosphorylated
tyrosine residues identified, prior to FGF2 stimulation, cells were
treated with sodium pervanadate to inhibit tyrosine phosphatase
activity and maximise the levels of tyrosine phosphorylated
peptides. Under these conditions, an additional 3 phosphotyrosine
containing peptides were identified, and the majority of the
previously identified phosphopeptides were present in greater
abundance (Figure 3B). Several additional serine residues were
also identified (Figure S1). Of the tyrosine residues identified, 5
phosphotyrosine peptides (pY252, pY485, pY525, pY540, pY602,
pY774) had a reduced SILAC ratio in the presence of SU5402
indicating that these particular sites within Eps8 are regulated by
FGFR kinase activity (Figure 3B). Four (pY485, pY525, pY602,
pY774) also had a reduced SILAC ratios in the presence of
dasatinib, indicating that these sites are regulated by SFK activity
(Figure 3B). One phosphopeptide (pY454) was identified but was
of too low abundance for ratio calculation. Data obtained in the
absence and presence of sodium pervandate were in agreement in
terms of the differential regulation of phosphorylation on these
sites. In the absence of tyrosine phosphatase activity, the number
of phosphotyrosine peptide identification events for site pY525 was
hugely increased, suggesting that this site is readily phosphorylated
but has a high turnover rate. Phosphorylation and dephosphor-
ylation of proteins at distinct sites can act as a molecular switch
regulating the association and disassociation of interacting
proteins. It may be that the Y525 is an important regulatory site
that is required to be turned over at a high frequency rate in order
to allow Eps8 function.
Our experiments have identified 16 of the 20 tyrosines present
within the human form of Eps8, the remainder being in regions of
the protein that were not detected. The total sequence coverage of
Eps8 is 68%. In the presence of FGF2, 7 of these tyrosine residues
are phosphorylated and for 6 of these a SILAC ratio could be
calculated. Residue pY540 shows no change in phosphorylation
due to the presence of the inhibitors, residue pY252 shows
a decrease in phosphorylation only in the presence of the FGFR
inhibitor, and the phosphorylation on residues pY485, pY525,
pY602, and pY774 are decreased in the presence of both the
FGFR and SFK inhibitor.
Phosphotyrosine Specific Interactions
In the presence of FGF2, we have identified specific sites of
tyrosine phosphorylation on Eps8. We have demonstrated
differential phosphorylation events on a number of these sites
that are dependent on activity of FGFR or SFKs. The distribution
of these sites on Eps8 is shown graphically in Figure 4A. Our aim
was to then further characterise these sites by identifying phospho-
dependent protein binding partners. To identify such potential
pTyr-dependent interacting partners for these residues in Eps8,
which may be involved in cellular processes downstream of FGFR,
we used a quantitative proteomic peptide pulldown (PPD)
approach [18]. Peptides containing the desired tyrosine residues
were synthesised in their phosphorylated and non-phosphorylated
forms. Using SILAC, we incubated heavy labelled (R10K8) HEK
293T cell lysates with phosphorylated peptide, medium labelled
(R6K4) lysates with non-phosphorylated peptide, and light lysates
(R0K0) were used as a no peptide control. All cells were treated
with FGF2 for 15 min prior to lysis. The huge advantage of using
SILAC over other techniques is that the specific binders can still be
identified in the presence of many non-specific proteins. Typically
a pull-down experiment will isolate not only specific interactors
but also background proteins that are binding to the bead matrix.
Proteins with SILAC ratios close to 1:1 can be discarded and only
those proteins that are significantly enriched in one of the
populations are regarded as ‘hits’. To qualify as a pY-dependent
binder in these PPD experiments, proteins had to have a HpY/
Mnon-pY and HpY/Lcontrol ratio at least 2 standard deviations
higher than the median (95% confidence). H/M and H/L ratios
for all proteins identified in each PPD experiment are plotted in
Figure S2. There are instances when peptides are identified only in
the heavy state and, therefore, not assigned a ratio. In these cases,
the mass spectra were manually checked to identify pY-peptide
specific interactors. Eighty-five distinct proteins with a range of
cellular functions were identified for the 7 pY-peptides (Figure 4B;
Table S2).
We have identified a number of SH2 or PTB domain-
containing proteins from our PPD assays which are likely to be
direct interacting partners for our phosphotyrosine peptides.
These proteins include known phosphotyrosine-binding proteins
Shp2 (PTPN11), Vav2 and Insulin receptor substrate 4 (IRS4). In
addition, four heavy labelled peptides identified as common to
both Src and CSK were enriched in the pY-PPD for residues 252
and 602. From this data it is not possible to discriminate between
these two proteins as they have high sequence homology, however,
Eps8 is known to bind to Src [9]. STAT3, another SH2 domain
containing protein, was identified in the pY525 PPD, with
a significantly increased HpY/Mnon-pY ratio (.95% confidence)
and an increased HpY/Lcontrol (.93% confidence). As both ratios
were not.95% confidence, STAT3 was not included in Figure 4B
and Table S2.
IRS4, Shp2 and WDR6 were identified as a potential novel
binding partners for the pY252 peptide. IRS4 acts as an interface
between receptor tyrosine kinases, such as IGF1R [29] and
FGFR1 [19], and SH2-containing intracellular signalling mole-
cules. It contains an IRS PTB domain, through which it can bind
Phosphoproteomics of Eps8
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to phosphorylated proteins. IRS4 is known to interact with both
Shp2 [30] and WDR6 [31,32,33], and all these proteins have been
implicated in FGFR signalling [19,20,34].
Eps8 has been shown to regulate receptor endocytosis via its
interaction with RN-Tre [5]. When bound to Eps8, RN-Tre,
a RabGAP, acts on Rab5 to inhibit EGFR internalisation [5]. We
have found several potential Eps8 binding proteins that also play
a role in endocytosis. Clathrin heavy chain was enriched
preferentially with pY485, pY525 and pY540 peptides, and
a component of the adaptor protein complex 2 (AP-2), AP-2
complex subunit beta-1 (AP2B1), with the pY525 peptide. AP-2 is
involved in clathrin-dependent endocytosis in which cargo
proteins become incorporated into clathrin-coated vesicles (CCVs)
which fuse with the early endosome. Recently Eps8 has been
shown to be recruited to clathrin-coated structures at the plasma
membrane [35] and, furthermore, we have found that FGFR
activation promotes clathrin-mediated endocytosis through Eps8
and Src [36]. Vav2, found enriched for pY454, regulates EGFR
receptor endocytosis and degradation [37] and NBR1, found
enriched for pY252, regulates the degradation of receptor tyrosine
kinases [38]. These proteins are potential novel Eps8 interactors
that may act downstream of FGFR.
Proteins involved in vesicular trafficking to and from the Golgi
apparatus include Arf5, a protein involved in vesicle budding from
the Golgi, identified in the pY485 PPD, coatamer subunit alpha
(COPA) in the pY774 PPD and both Sec23A and general vesicular
transport factor p115 (USO1) in the pY525 PPD.
A cluster of proteins involved in nucleocytoplasmic transport
were found bound to pY485, pY525, and pY540: the small
GTPase Ran, Importin-5 (IPO5), importin subunit beta 1
(KPNB1), Exportin-2 (CSE1L), Exportin-7 (XPO7), and Trans-
portin-1 (TNPO1). A number of these proteins are known to bind,
either in isolation, or together with an adapter protein, to nuclear
localisation signals (NLSs) in cargo proteins. As an NLS is
a positively charged sequence, it is possible that these proteins can
bind preferentially to peptides containing basic residues. Peptide
540 is a potential candidate for this, having 4 lysine residues in
close proximity. However, each of these proteins is enriched
specifically for the pY form of the peptide, arguing against lysine-
dependent binding. Eps8 contains a putative NLS between
residues 299–309 [8], but has not been reported to be present in
the nucleus.
Out of the many proteins identified that have functions in
protein trafficking, whether it be from the plasma membrane, to
and from the Golgi, or to and from the nucleus, a significant
number of them are associated with the pY525 peptide.
Interestingly this is the site that we find to have a high turnover
rate, suggesting a functional role in a dynamic cellular process.
MAPKAP1 (Sin1) was recruited to the pY252 peptide.
MAPKAP1 interacts with mammalian target of rapamycin
(mTOR) and is found in the mTOR complex 2 (mTORC2)
[39,40,41]. Interestingly, Eps8 has been shown to regulate the
expression of FAK via the mTor/STAT3 pathway [11]. Eps8
overexpression leading to increased activity of FAK via this
pathway has been shown to promote disease progression in colon
cancer [11]. MAPKAP1 may be a physical link to this pathway. As
previously mentioned, STAT3 was also identified in the pY525
PPD. Additionally, STAT3 has been linked to FGFR in tumour
cells where it can interact with amplified receptor [42].
Other potentially interesting putative Eps8 binding partners
that we have identified that could link Eps8 to FGFR signalling
include LRPPRC, which has previously been co-purified with the
FGFR complex [43], and PHB which is required for Ras-
mediated Raf-MEK-ERK activation [44].
Several RNA-binding proteins have been found in our PPDs. It
has been reported previously that RNA-binding proteins can bind
preferentially to the negative charge on the phosphorylated
peptides, thus appearing as specific binders when they are actually
contaminants [18].
Novel Eps8 Binding Partners
Without further validation proteins identified in peptide pull-
down assays can only be described as potential interactors. It may
be that the interactions are not biologically relevant, or when the
full length protein is in its folded conformation the interactions
detected between peptide and protein are not sterically possible. In
addition contaminants arising from interactions with the bead
matrix may be present. Common IP contaminants, described as
the ‘bead proteome’ are listed and scored in the ‘protein frequency
library’ (used to identify the frequency with which proteins appear
in a subset of IPs using a particular type of beads) [45,46]. This
library can help in discriminating between those proteins that are
true interactors and those that may be bead contaminants. The
majority of proteins identified both here, and with a high
frequency (68–92%) in experiments compiled in the protein
frequency library [46] are RNA-binding proteins: 60S ribosomal
protein (RPL22), SERBP1, ATP-dependent RNA helicase
DDX3X, splicing factor 3B subunits 1 and 2 (SF3B1, SF3B2),
DEAD box protein 41 (DDX41). Hence further validation is
required to identify ‘true’ protein-protein interactions.
In an attempt to further validate potential protein-protein
interactions we used co-immunoprecipitation to pull down Myc-
tagged Eps8 protein from FGF2 stimulated HEK 293T cells and
probed for proteins of interest (Figure 5). The interactions between
Eps8 and AP-2 and clathrin, proteins important in clathrin-
mediated endocytosis, have been confirmed. This further supports
evidence that Eps8 plays an important role in endocytic
trafficking. In addition, we confirm the novel interactions between
Eps8 and Shp2, Vav2, NBR1, LRPPRC, PHB, PHB2 and IRS4.
It must be noted that, although co-immunoprecipitation experi-
ments such as these can confirm protein-protein interactions it is
acknowledged that they detect both direct and indirect interac-
tions.
The Novel Interaction between Eps8 and IRS4 is FGF2
Dependent
FGF2 activation of FGFR1 and FGF7 activation of FGFR2
results in phosphorylation of IRS4 on residue 921 [19,20].
Phosphorylation of IRS4 promotes the formation of a complex
with Shc, which may link IRS4 directly to activated receptor, and
also allows recruitment of Grb2, PLCc and PI3K thus promoting
downstream signalling [19]. In our PPDs IRS4 was identified as
a potential novel binding partner for the Eps8 peptide containing
phosphorylated Tyr252, a residue shown to be sensitive to the
addition of the FGFR kinase inhibitor, SU5402 and not the SFK
inhibitor, dasatinib (Figures 3 and 4). Furthermore, the Eps8-IRS4
protein-protein interaction was confirmed by subsequent co-
immunoprecipitation experiments with Myc-Eps8 in FGF2
stimulated cells (Figure 5). Next, as eluded to in the peptide pull
down assays, we investigated whether the Eps8-IRS4 interaction
within cells is dependent upon FGF2 activation and, therefore,
sensitive to the addition of SU5402 but not dasatinib. Co-
immunoprecipitation experiments were performed in the presence
and absence of FGF2, SU5402 and dasatinib (Figure 6). The
association between Myc-Eps8 and IRS4 increases in the presence
of FGF2 (Figure 6A). Pre-treatment with SU5402 causes an
inhibition of this interaction, indicating this increased association is
due to activation of the FGF receptor. This FGF2 dependent
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increase in the association is not affected by the presence of
dasatinib and, therefore, not dependent on SFK phosphorylation.
An increase in phosphorylation of both Eps8 and IRS4 is seen
upon FGF2 activation as previously reported [8,19]. Both Eps8
and IRS4 are tyrosine phosphorylated in response to FGF2 in
HEK 293T cells (Figure 6A) and remain so throughout the
duration of receptor activation (Figure 6B). The interaction
between Eps8 and IRS4 has been confirmed using endogenous
levels of both proteins (Figure 6C). Co-immunoprecipitation of
endogenous levels of Eps8 and IRS4 only in the presence of FGF2
and FGF2 with dasatinib, both conditions where FGF receptor is
active, confirm that this interaction is FGF dependent (Figure 6D)
as seen with overexpressed Eps8. Cell imaging data using
fluorescently tagged proteins confirm these results. Following
FGF2 stimulation, Eps8 colocalises with IRS4 in NIH 3T3 cells
within the cytoplasm (Figure 7). This colocalisation is decreased
following the addition of SU5402 indicating that it is dependent
upon activated FGFR. These data, together with the peptide pull
down data suggests that the interaction between Eps8 and IRS4
may occur on residue 252 of Eps8 when it is a phosphorylated
state and whose phosphorylation is dependent upon FGFR
activation.
Conclusions
Here we have used quantitative proteomics to study the
phosphorylation of Eps8 and phosphotyrosine dependent binding
of proteins to it. Clusters of proteins with distinct cellular functions
have been identified, including a large number involved in
trafficking, either from the cell membrane, the Golgi or from
cytoplasm to nucleus and vice versa. Most of the proteins identify
are potential novel interactors, and further studies are needed to
validate some of these interactions. The validated interactions
between Eps8 and clathrin and AP-2, provide further evidence to
support the role of Eps8 in receptor mediated endocytosis. Also,
the interaction between Eps8 and IRS4, together with the
knowledge that IRS4 is involved in downstream signalling from
the FGF receptor, is an interesting lead into the role of Eps8 in
FGFR signalling. In conclusion, Eps8 is a multi-functional adaptor
protein which may have the capabilities of integrating receptor
trafficking, cellular signalling, and protein degradation.
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inhibitor, prior to FGF2 stimulation. Myc-Eps8 was immunopre-
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